Mesoblast (MEOBF) Net Income towards Common Stockholders (2014 - 2023)

Mesoblast has disclosed Net Income towards Common Stockholders across 10 years of filings, most recently posting -$23.9 million for Q2 2023.

• In Q2 2023, Net Income towards Common Stockholders fell 11.59% year-over-year to -$23.9 million; the TTM figure through Jun 2023 stood at -$83.9 million (up 8.14% YoY), while the FY2026 annual figure was -$57.5 million, up 44.8% from the prior year.
• Net Income towards Common Stockholders came in at -$23.9 million for Q2 2023 at Mesoblast, down from -$18.6 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$5.5 million in Q3 2019 to a low of -$45.3 million in Q1 2020.
• Average Net Income towards Common Stockholders over 5 years is -$23.9 million, with a median of -$24.5 million recorded in 2022.
• Year-over-year, Net Income towards Common Stockholders soared 71.87% in 2019 and slumped 347.56% in 2020.
• Over 5 years, Net Income towards Common Stockholders stood at -$30.1 million in 2019, then rose by 14.55% to -$25.7 million in 2020, then decreased by 0.98% to -$25.9 million in 2021, then rose by 5.62% to -$24.5 million in 2022, then increased by 2.22% to -$23.9 million in 2023.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$23.9 million in Q2 2023, -$18.6 million in Q1 2023, and -$24.5 million in Q4 2022.